Cipla, Kemwell form JV

Pharma firm Cipla and Kemwell Biopharma on Wednesday announced the execution of a joint venture agreement to develop, manufacture and commercialise biosimilars for global markets. For this purpose, a joint venture company shall be incorporated with an aim to enter the respiratory biosimilars space, Cipla said in a regulatory filing. Under the terms of the pact, the joint venture will leverage Cipla and Kemwell's complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing, and commercialisation of biopharmaceutical products, it added.